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Abstract
Background: Vaccines that activate strong specific Th1-predominant immune responses are critically needed for many
intracellular pathogens, including Leishmania. The requirement for sustained and efficient vaccination against leishmaniasis
is to formulate the best combination of immunopotentiating adjuvant with the stable antigen (Ag) delivery system. The aim
of the present study is to evaluate the effectiveness of an immunomodulator on liposomal Ag through subcutaneous (s.c.)
route of immunization, and its usefulness during prime/boost against visceral leishmaniasis (VL) in BALB/c mice.
Methodology/Principal Findings: Towards this goal, we formulated recombinant GP63 (rGP63)-based vaccines either with
monophosphoryl lipid A-trehalose dicorynomycolate (MPL-TDM) or entrapped within cationic liposomes or both.
Combinatorial administration of liposomes with MPL-TDM during prime confers activation of dendritic cells, and induces an
early robust T cell response. To investigate whether the combined formulation is required for optimum immune response
during boost as well, we chose to evaluate the vaccine efficacy in mice primed with combined adjuvant system followed by
boosting with either rGP63 alone, in association with MPL-TDM, liposomes or both. We provide evidences that the presence
of either liposomal rGP63 or combined formulations during boost is necessary for effective Th1 immune responses (IFN-c,
IL-12, NO) before challenge infection. However, boosting with MPL-TDM in conjugation with liposomal rGP63 resulted in a
greater number of IFN-c producing effector T cells, significantly higher levels of splenocyte proliferation, and Th1 responses
compared to mice boosted with liposomal rGP63, after virulent Leishmania donovani (L. donovani) challenge. Moreover,
combined formulations offered superior protection against intracellular amastigote replication in macrophages in vitro, and
hepatic and splenic parasite load in vivo.
Conclusion: Our results define the immunopotentiating effect of MPL-TDM on protein Ag encapsulated in a controlled
release system against experimental VL.
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Introduction
Leishmaniasis represents infections caused by obligate heterog-
enous kinetoplastid protozoan parasites, Leishmania, transmitted by
the bite of infected female sand fly Phlebotomus. It afflicts hundreds
of thousands of people in tropical and subtropical areas every year,
is currently endemic in 88 countries, and poses a threat to 350
million people worldwide [1,2]. The spectrum of leishmaniasis
ranges from self-limiting cutaneous lesions to severe chronic
mucocutaneous infections to fatal visceral disease. The latter is
responsible for 59,000 death tolls every year, a parasitic disease
statistics surpassed by malarial infections [3]. Conventional
chemotherapies are often inadequate, toxic and expensive or are
becoming less effective because of the emergence of resistance, a
clear risk for human health. Extensive studies reveal that
leishmaniasis is one of the parasitic diseases that can be controlled
by vaccination [4]. Until recently, live virulent L. major
(leishmanization) was the best vaccine against human cutaneous
leishmaniasis (CL). However, this process was discontinued due to
uncontrolled long-lasting skin lesions, the spread of HIV co-
infection and the use of immunosuppressive drugs. Despite recent
advances in immunology and determination of the factors that
control the development of protective immune response in
leishmaniasis, there are no available human vaccines against any
form of leishmaniasis [5].
It is believed that persistence of a small number of parasites at
the site of infection can trigger infection-induced immunity against
CL [6]. This immunity requires the presence of leishmanial
antigen (Ag) only rather than live replicating parasites [7]. An
alternate way is to promote Ag exposure at the site of inoculation
or to prevent Ag clearance using appropriate adjuvants like
liposomes. Our group has recently demonstrated that stable
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cationic liposomes acted as a potent adjuvant to induce long-
lasting protection against experimental visceral leishmaniasis (VL)
[8,9]. However, these results were obtained through intraperito-
neal (i.p.) immunization and without the use of any immunomod-
ulator. The major obstacle to the development of this vaccine for
human use is the route of immunization. Since the route of
vaccination influences the development of immune responses for
protection, or failure of protection [10], the results obtained with
i.p. immunization cannot be extrapolated to the clinically relevant
subcutaneous (s.c.) route. Therefore to increase the prophylactic
efficacy of liposomal protein vaccination through s.c. route against
experimental VL, strategies are being attempted by choosing the
best combination of adequate adjuvant with the vaccine delivery
vehicle.
The traditional paradigm of s.c. immunization proposes
involvement of skin derived dendritic cells (DCs), as biosensors,
in Ag presentation that modulate the immune responses to the
environmental stimuli. Despite the fact that delivery of liposomal
Ag through s.c. route of immunization hindered the Ag uptake by
draining lymph nodes (DLN) due to breakdown of liposomes in
dermis [11], a cationic liposomal formulation with the synthetic
mycobacterial immunomodulator (CAF01) exhibited substantial
immune responses through activation of DCs against Mycobacteri-
um, Chlamydia, and malaria [12]. Since the function of the
liposomal formulation relied on the immunomodulator, successful
liposomal vaccination would probably require an appropriate
adjuvant along with the Ag delivery system. We chose cationic
liposomal formulation with monophosphoryl lipid A (MPL) as the
immunomodulator, a target for the intracellular Toll like receptor
4 (TLR4) with an extensive history of use in humans. MPL has
been used as an adjuvant in several human clinical trials, including
vaccines for tuberculosis, malaria, hepatitis B, and leishmaniasis
[13–16].
However, the combinatorial use of immune potentiator with
suitable delivery vehicle against VL has received minimum
attention.
In the current study, we developed vaccination strategies using
liposomal protein in association with MPL-TDM (monopho-
sphoryl lipid A- trehalose dicorynomycolate) with proven vacci-
nation efficacy through s.c. immunization in susceptible BALB/c
mice against experimental VL. As the vaccine Ag we chose
recombinant GP63 (rGP63) from Leishmania donovani whose native
form has been shown to be highly protective against VL in BALB/
c mice [8]. Here in this study, we analyzed the potentiating effects
of distearoylphosphatidyl choline (DSPC)-bearing cationic lipo-
somes in presence of MPL-TDM for the first time. To this end, we
monitored the involvement of DCs in the antigen presentation for
activation of effector T cells, leishmanicidal activity of macro-
phages and role of T cells in eliciting protective immunity.
Additionally we examined the impact of MPL-TDM and
liposomes on prime-boost.
Materials and Methods
Mice and parasites
Studies were performed with 4–6 weeks old female BALB/c
mice reared in the animal care facility of the Indian Institute of
Chemical Biology under pathogen free conditions. All animal
studies were done according to the Committee for the Purpose of
Control and Supervision on Experimental Animals (CPCSEA),
Ministry of Environment and Forest, Govt. of India, and approved
by the animal ethics committee (147/1999/CPSCEA) of Indian
Institute of Chemical Biology. An Indian strain of L. donovani
(MHOM/IN/83/AG83) was originally isolated from an Indian
Kala-azar patient and maintained by serial passage in Syrian
hamsters as described earlier [17]. The parasites were cultured as
promastigotes at 22uC in Medium 199 (Sigma-aldrich, St. Louis,
MO) supplemented with 2 mM glutamine, 25 mM HEPES,
penicillin G sodium (100 U/ml), streptomycin sulphate (100 mg/
ml) and 10% heat inactivated fetal bovine serum (FBS) (Gibco/
BRL Life Technologies, Grand Island, USA). Parasites from
stationary-phase culture were sub-cultured to maintain an average
density of 26106 cells/ml.
Generation of recombinant protein and entrapment in
DSPC-bearing cationic liposomes
A plasmid containing full-length gp63 from L. donovani
(pET16bLdgp63) was generated, expressed and purified as described
previously [18].
Liposomal rGP63 was prepared by incorporation of rGP63 into
the lipid bilayer of DSPC, cholesterol (Sigma-aldrich) and
stearylamine (Fluka, Buchs, Switzerland) at a molar ratio of
7:2:2 and dissolved in chloroform followed by evaporating the
organic solvents to form a thin film as described earlier [8]. Empty
and Ag entrapped liposomes were prepared by dispersion of lipid
film in either 1 ml of PBS alone or containing 250 mg/ml of Ag
(rGP63). The mixture was then vortexed and sonicated in an
ultrasonicator (Misonix, New York, USA) for 30 s, followed by
incubation at 4uC for 2 h. The excess free rGP63 was removed by
centrifugation at 100,0006 g for 1 h at 4uC. The level of
incorporation ranged between 65–70%.
Immunization and challenge of infection
BALB/c mice were immunized s.c. two times at an interval of 2
weeks with 2.5 mg of rGP63 either free or entrapped within
DSPC-bearing cationic liposomes, and or mixed with 25 mg of
Sigma adjuvant system or MPL-TDM in a total volume of 100 ml.
PBS, only liposomes, only MPL-TDM and liposomes mixed with
MPL-TDM serve as controls. At 1 and 3 wks post-immunization,
groups of mice were sacrificed for the analysis of immune
response. In other experiments, mice were primed with liposomal
rGP63 in association with MPL-TDM, followed by boosted with
either rGP63 alone, or in association with MPL-TDM, liposomes
Author Summary
Visceral leishmaniasis (VL), a vector-transmitted disease
caused by Leishmania donovani, is potentially fatal if left
untreated. Vaccination against VL has received limited
attention compared with cutaneous leishmaniasis, al-
though the need for an effective vaccine is pressing for
the control of the disease. Earlier, we observed protective
efficacy using leishmanial antigen (Ag) in the presence of
either cationic liposomes or monophosphoryl lipid A-
trehalose dicorynomycolate (MPL-TDM) against experi-
mental VL through the intraperitoneal (i.p.) route of
administration in the mouse model. However, this route
of immunization is not adequate for human use. For this
work, we developed vaccine formulations combining
cationic liposomes with MPL-TDM using recombinant
GP63 (rGP63) as protein Ag through the clinically relevant
subcutaneous (s.c.) route. Two s.c. injections with rGP63 in
association with cationic liposomes and MPL-TDM showed
enhanced immune responses that further resulted in high
protective levels against VL in the mouse model. This
validates the combined use of MPL-TDM as an immuno-
potentiator and liposomes as a suitable vaccine delivery
system.
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or both. For experimental infections, mice were challenged 3
weeks post-immunization with 2.56107 freshly transformed
stationary-phase promastigotes in 200 ml PBS injected via the tail
vain as reported previously [17].
Antigen presenting capacity of DC
Two days after immunization, DCs obtained from draining
inguinal nodes were collected from the mice immunized with PBS,
MPL-TDM plus liposome, and liposomal rGP63 plus MPL-TDM,
and the Ag- presenting capacity was studied. In brief, lymph nodes
(LN) were passed through 100 mm cell strainer and digested for
30 min at 37uC by 1 mg/ml of collagenase D (Roche Diagnostics,
Mannheim, Germany). DCs were positively isolated by using
magnetized anti CD11c+ magnetic-activated cell sorting columns
(Miltenyi Biotec, Auburn, CA) according to manufacturers’
protocol and the purity was simultaneously checked by flow
cytometry. To detect the Ag presenting capability of DCs, CD4+ T
cells were isolated from mice vaccinated with rGP63 through
magnetized anti CD4+ antibody by positive selection. 26105
CD4+ T cells were co-cultured with 26105 CD11c+ and CD11c2
cells isolated from mice vaccinated with either liposomal rGP63
mixed with MPL-TDM, liposome plus MPL-TDM or PBS.
Supernatants were collected 24 h later and assayed for IL-2 by
sandwich ELISA using OptEIA kit (BD Pharmingen, San Diego,
CA).
Derivation and stimulation of bone-marrow derived
dendritic cell (BMDC)
BMDCs were generated by culturing cells isolated aseptically
from tibias and femurs of BALB/c mice in the presence of GM-
CSF and IL-4 as reported previously [19]. Briefly, bone ends were
cut and marrow flashed out with complete RPMI-1640, passed
through a nylon mesh to remove small pieces of muscles and debri.
Cells were pelleted by centrifugation at 390 g for 10 min and
resuspended in complete RPMI medium containing rGM-CSF
(40 ng/ml) and rIL-4 (30 ng/ml) supplemented with 10% FCS at
a density of 1.56106/ml cells in 24 well plates. Two-thirds of the
medium was replaced on day 4 of culture and maintained for
additional 3 days inside 5% CO2 at 37uC. On day 8 of culture,
most non-adherent and loosely adherent cells had acquired typical
DC morphology and the phenotype was evaluated by flow-
cytometry. On day 8, cells were collected, washed twice with ice-
cold PBS, and adjusted to 16106 cells/ml in complete RPMI-1640
with 10% FCS and incubated in 24 well-plates with the adjuvants
being tested. Supernatants were collected on days 1, 2, 3 and
analyzed for IL-12 (p40) and Nitric oxide (NO).
Measurement of delayed-type hypersensitivity (DTH) in
mice
DTH was determined as an index of cell mediated immune
response as described earlier [20]. The response was evaluated by
measuring the difference of the footpad swelling at 24 h following
intradermal immunization of the test footpad with 25 ml of rGP63
(200 mg/ml) from that of control (PBS-injected) footpad with a
constant pressure calliper.
Measurement of rGP63-specific antibody response
The levels of Ag-specific serum IgG and its different isotypes
IgG1 and IgG2a was determined in serum samples from
experimental mice before and after infection by ELISA. In brief,
96-well microtiter plates (Maxisorp, Nunc) were coated with
rGP63 (5 mg/ml) diluted in 0.02 M phosphate buffer (pH 7.5)
overnight at 4uC. The plates were blocked with 1% BSA in PBS at
room temperature for 3 h to prevent non-specific binding. After
washing with PBS containing 0.05% Tween-20 (Sigma), the plates
were incubated with 1:1000 dilutions of mice sera at 4uC. The
next day, the plates were incubated for 3 h at room temperature
with horseradish peroxidase-conjugated goat anti-mouse IgG1 or
IgG2a diluted 1:500 in blocking buffer. Substrate solution
(0.8 mg/ml o-phenylene diamine dihydrochloride 0.05 M phos-
phate-citrate buffer pH 5.0 containing 0.04% H2O2) (100 ml) was
added for 30 min. The absorbance was determined using an
enzyme-linked immunosorbent assay (ELISA) plate reader
(Thermo, Waltham, MA) at 450 nm.
T cell proliferation assay and Cytokine ELISA
The spleen cells were aseptically removed from the immunized
and infected BALB/c mice and single cell suspensions were
prepared in RPMI 1640 supplemented with 10 mM NaHCO3,
10 mM HEPES, 100 U/ml penicillin, 100 mg/ml streptomycin
sulphate, 50 mM 2-ME and 10% heat inactivated fetal bovine
serum. Erythrocytes were removed by lysis with 0.14 M Tris
buffered NH4Cl. The splenocytes were then washed twice,
resuspended in the culture medium and viable mononuclear cell
number was determined by Trypan blue exclusion [21]. Then the
cells were cultured in a triplicate in a 96-well flat bottom plate at a
density of 26105 cells/well in a final volume of 200 ml and
stimulated with rGP63 (2.5 mg/ml). The supernatants collected
were stored at 270uC for cytokine analysis. Measurement of IFN-
c, IL-2, IL-12(p40), IL-4, IL-10 levels was carried out as detailed in
the instructions supplied with a cytokine ELISA kit (BD
Biosciences).
Measurement of nitric oxide (NO) production
The accumulation of nitrite in the culture medium was
measured as described previously [21]. Briefly, 100 ml of
splenocyte culture supernatants were mixed with an equal volume
of Griess reagent (1% sulfanilamide and 0.1% N-1-naphthylethy-
lene diamine hydrochloride in 50% H3PO4) and incubated at
room temperature for 10 min. Absorbance was then measured at
540 nm.
Evaluation of macrophage infection
At 3 weeks after the last booster immunization, macrophages
collected from peritoneal exudates of vaccinated mice were
allowed to adhere to cover slips in 0.5 ml RPMI 1640 containing
10% FCS at 37uC in 5% CO2. Nonadherent cells were removed
by washing with warm PBS after 2 h. Macrophages were infected
with promastigotes on glass cover slips (18 mm2; 106 macrophages
per cover slip) in 0.5 ml of RPMI/10% FCS at a ratio of
approximately 10 parasites/macrophage for 4 h. The unphago-
cytosed parasites were removed by warm PBS washing, and the
infected macrophages were further incubated in complete medium
for 72 h at 37uC in 5% CO2. The cells were then fixed in
methanol followed by staining with Giemsa for determination of
intracellular parasite numbers. Prior to fixation, culture superna-
tants were removed at 72 h and frozen at 270uC for cytokine
analysis.
Evaluation of parasite burden in liver and spleen
Parasite load was evaluated by limiting dilution assay (LDA)
with slight modifications [22]. Briefly, a weighted piece of liver and
spleen were isolated from mice and homogenized in complete
Schneider’s Drosophila Medium (Invitrogen, Grand Island, USA)
containing 10% heat inactivated FCS and diluted with a same
medium to a final concentration of 1 mg/ml. Five-fold serial
MPL-TDM with Liposomal Antigen Elicits Immunity
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dilutions of homogenized tissues were cultured in a 96 well tissue
culture plate (Nunc, Rosklide, Denmark) for one month at 22uC.
The reciprocal of the highest dilution that was positive for parasite
growth was considered to be the concentration of parasites per mg
of tissue. The total organ burden was calculated using the weight
of the respective organs.
Flow cytometry
For intracellular analysis of IFN-c produced by CD4+ and
CD8+ T lymphocytes of vaccinated and infected mice, flow-
cytometry (FACS Canto, BD Biosciences) using FACS Diva
Software was carried out. All the antibodies were purchased from
BD pharmingen. Single-cell splenocyte suspensions were stimu-
lated overnight with 5 mg/ml rGP63 or left unstimulated.
Brefeldin A (10 mg/ml) was added to the cultures 2 h before
harvest. The cells were then washed in PBS containing 0.1%
NaN3 and 1% FCS at 4uC and stained with PE-conjugated anti-
CD3, PerCP Cy5.5 conjugated anti-CD4 and FITC-conjugated
anti-CD8 mAb at 4uC for 30 min. The cells were then
permeabilized with Cytofix/Cytoperm (BD Biosciences) solution
for 20 min at 4uC, and then stained with APC conjugated anti-
IFN-c mAb. After incubation at 4uC for 30 min in the dark, cells
were washed with wash buffer and re-suspended in staining buffer
prior to analysis.
Statistical analysis
One-way ANOVA statistical test was performed to assess the
differences among various groups. Multiple comparisons Tukey-
Kramer test was used to compare the means of different treatment
groups using the GraphPad InStat software. In some experiments
two-tailed Student’s t test was performed. A value of p,0.05 was
considered to be significant.
Results
Subcutaneous immunization with cationic liposomal
rGP63 and MPL-TDM generated early immune responses
We have previously shown that the i.p. administration of native
GP63 in association with DSPC bearing cationic liposomes was
sufficient to confer durable immunity against BALB/c mice
challenged with virulent L. donovani [8]. To design effective
strategies that are crucial in s.c. immunization, we developed and
optimized suitable vaccine preparations using recombinant form
of L. donovani GP63 adjuvanted with either MPL-TDM or cationic
DSPC liposomes or both.
Mice were immunized with rGP63 alone or in association with
either MPL-TDM, liposomes or both and the immune response
was investigated by rGP63-specific immunity (Figure 1). Since
DTH response is the measure of cell mediated immunity in vivo
[20], we found mice receiving either rGP63 alone, in association
with either MPL-TDM, liposomes or combined with both
adjuvants showed significantly higher response compared to
controls just 1 wk after final vaccination (data not shown) and
maintained thereafter up to 3 weeks (Figure 1A). Mice vaccinated
with liposomal rGP63 mixed with MPL-TDM, however, exhibited
significantly higher level of DTH compared to mice receiving
Figure 1. Induction of DTH and cytokine response in liposomal rGP63 plus MPL-TDM vaccinated mice. DTH and rGP63-specific cytokine
analysis in mice vaccinated with either rGP63 alone, or in association with MPL-TDM, or DSPC-cationic liposomes, or both 3 weeks after final
immunization. A. DTH response was determined as described in the Materials and Methods. Spleens were collected, splenocytes were restimulated in
vitro for 72 h with 2.5 mg/ml of rGP63 and levels of (B) IFN-c, (C) IL-12(p40), and (D) IL-4 were measured. All the results are mean 6 S.E. of five
individual mice per group, representative of two independent experiments with similar results. ***p,0.001 assessed by one-way ANOVA and Tukey’s
multiple comparison tests, compared to PBS, unless stated.
doi:10.1371/journal.pntd.0001429.g001
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either rGP63 alone or mixed with MPL-TDM (p,0.001)
(Figure 1A).
We next analyzed the cytokine responses in splenocytes isolated
from vaccinated mice, following stimulation with Ag. The assays for
IFN-c, and IL-12 p40 production from immunized mice showed that
vaccination with liposomal rGP63 mixed with MPL-TDM exhibited
substantially higher immune response 1 week after final immunization
(data not shown) and was further enhanced at 3 weeks post vaccination
(Figures 1B and 1C). Moreover, mice vaccinated with liposomal
rGP63 in association with MPL-TDM showed significantly higher
IFN-c and IL-12 p40 than the mice receiving rGP63 plus MPL-TDM
or liposomal rGP63 (p,0.001). Interestingly, the IL-4 response was
also clearly evident in the mice receiving rGP63 combined with two
adjuvants and was significantly higher than the mice receiving rGP63
with MPL-TDM or liposomes (p,0.001) (Figure 1D).
In vitro analysis of mice sera obtained after the final immunization
demonstrated that animals vaccinated with rGP63 adjuvanted with
either MPL-TDM, or cationic liposomes or both generated
enhanced levels of IgG2a (associated with Th1-biased response).
Moreover, combining liposomal rGP63 with MPL-TDM resulted in
a significantly high IgG2a compared to mice receiving MPL plus
rGP63 or liposomal rGP63 (p,0.001) (Figure S1A). Although low
level of serum IgG1 was observed in all vaccinated mice, maximum
generation was observed in mice vaccinated with liposomal rGP63
alone, and combined with MPL-TDM (Figure S1B). These data
suggest that s.c. immunization with rGP63 adjuvanted with
combined adjuvants elicited significant cellular and humoral
immunity at 3 weeks with early mixed Th1/Th2 immune response.
Adjuvanting effects of DSPC-bearing cationic liposomes
and MPL-TDM on BMDC activation
It has been previously reported that TLR4 agonists like MPL
can induce DCs to produce high levels of proinflammatory
cytokines [23,24], usually to a lower extent than its related
compound LPS. To optimize formulations for prophylactic use,
we investigated innate signals on DCs induced by MPL in
presence or absence of cationic DSPC liposomes. Thus, we
assessed the adjuvanticity of cationic DSPC liposomes, MPL-
TDM and combined formulation (MPL-TDM plus liposomes) on
DCs derived from the bone marrow of BALB/c mice. As shown in
Figure 2A, culture with MPL-TDM, or cationic DSPC liposomes
stimulated relatively high levels of IL-12 (p40). Interestingly,
combining MPL-TDM with DSPC bearing cationic liposomes
resulted in release of significantly higher levels (1100643.3 pg/ml)
of IL-12 (p40) compared to MPL-TDM (873.3630.32 pg/ml)
(p,0.05) or cationic DSPC liposomes (553.3640.55 pg/ml)
(p,0.001) and the response with the combinations was compa-
rable to LPS (101367.26 pg/ml). Similarly, upon combined
stimulation with MPL-TDM and cationic DSPC liposomes, the
NO production from BMDCs was greatly increased
(37.3365.2 mM) and were significantly higher than MPL-TDM
(2562.8 mM) (p,0.01) and liposomes (2262.64 mM) (p,0.01)
(Figure 2B). These data indicated that combining MPL-TDM with
cationic DSPC liposomes resulted in increased adjuvant activity on
DCs in vitro. Taken together, these data illustrated the rational for
using combined vaccine formulations to obtain the sustained
immune responses in BALB/c mice.
Figure 2. Activation of DCs in the generation of immune responses. A. Bone-marrow derived DCs were isolated and stimulated with LPS
(1 mg/ml), liposomes (50 mM), MPL-TDM (100 ng/ml) and combination of liposomes (50 mM) and MPL-TDM (100 ng/ml) on activation of BMDCs. The
release of IL-12 (p40) (A) and NO (B) were measured subsequently. The results are duplicate mean 6 S.E, representative of three independent
experiments with similar results. *p,0.05, **p,0.01, ***p,0.001 assessed by two-tail t test. C. Ag-presenting capacity of CD11c+ and CD11c2 cells
isolated from mice immunized with PBS, MPL-TDM plus liposomes, and liposomal rGP63 plus MPL-TDM. CD11c+ and CD11c2 cells were isolated from
LN as described in Materials and Methods and IL-2 content was assayed through ELISA.
doi:10.1371/journal.pntd.0001429.g002
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Ag presentation by lymph node dendritic cells (LNDCs)
DCs, the most potent APC of the immune system, play a crucial
role in priming T cell immunity during Leishmania infection [25].
However, the activation of T cells by DCs depends on their state of
processing, maturation and activation. Since the finding that s.c.
immunization with cationic liposomal rGP63 in association with
MPL-TDM demonstrated highest immune response after vacci-
nation, we explored whether the early immune responses were due
to activation of T-cells through draining node DCs. Naı¨ve BALB/
c mice were immunized s.c. with liposomal rGP63 mixed with
MPL-TDM. Injections with PBS and liposomes mixed with MPL-
TDM served as controls. We isolated both CD11c+ and CD11c2
cells from the LN draining the immunization site after 2d of
immunization and co-cultured with CD4+ T cells isolated from
mice immunized with liposomal rGP63 through i.p. route.
Figure 2C illustrates that CD11c+ cells isolated from mice
receiving liposomal rGP63 in combination with MPL-TDM,
induced substantial amount of IL-2 from CD4+ T cells suggesting
the ability of DCs to activate T cells. These data thus exemplified
the role of DCs in the Ag presentation and concomitantly highlight
the stimulatory effects of the vaccine comprising combined
adjuvants on the immune system.
Cellular and humoral responses prior L. donovani
infection in mice primed with liposomal rGP63 and MPL-
TDM, followed by boosting with either rGP63 alone, or in
association with MPL-TDM, liposomes, or both
Based on the result obtained above, it appeared that above
MPL-TDM in presence of liposomes contributed to the adjuvant
effect of the liposomal rGP63 based protein vaccine. We further
examined whether the combined adjuvant formulation was
required for boosting to obtain maximal responses. To address
this point, we developed several vaccine regimens in which
priming was carried out using liposomal rGP63 in association with
MPL-TDM, while boosting was either with rGP63 alone, in
association with MPL-TDM, with DSPC liposomes, or both.
Boosting with rGP63 either with MPL-TDM, cationic lipo-
somes or both showed comparable level of DTH, Ag-specific
splenocyte proliferation, and IL-2 production (data not shown) 3
weeks after final vaccination. Significant enhancement of both the
IgG2a and IgG1 isotypes with a dominance of IgG2a were
observed in mice boosted with either rGP63 in association with
MPL-TDM, or liposomes or both (Figure S2). However, mice
boosted with liposomal rGP63 with (492.6611.4 pg/ml IFN-c,
183.266.8 pg/ml IL-12 p40) or without MPL-TDM
(480.8612.8 pg/ml IFN-c, 174.266.46 pg/ml IL-12 p40) elicited
comparable level of Th1 cytokine responses (IFN-c, IL-12 p40)
and the magnitude was significantly higher (p,0.001) than the
group of mice boosted with rGP63 plus MPL-TDM (345621 pg/
ml IFN-c, 93.266.1 pg/ml IL-12 p40) (Figures 3A and 3B) 3
weeks after final vaccination.
Furthermore, IL-4 response was significantly higher in mice
boosted with liposomal rGP63 with or without MPL-TDM
(Figure 3D) compared to PBS control (p,0.001). In addition,
although highest level of NO was produced by splenocytes of mice
boosted with liposomal rGP63 in association with MPL-TDM, the
response was not significantly higher than mice boosted with
liposomal rGP63 (Figure 3C).
We next further compared and analyzed the IFN-c producing
CD4+ and CD8+ T cells in mice boosted with various vaccine
potentials by intracellular cytokine staining through flow cytom-
etry. Mice boosted with rGP63 alone showed significantly higher
IFN-c producing CD4+ (3.060.4%) as well as IFN-c producing
CD8+ T cells (1.460.2%) over PBS (p,0.01) immunized group
(Figure 4). Moreover, mice boosted with rGP63 plus MPL-TDM
showed significantly higher expression of CD4+ IFN-c+
(4.160.3%; p,0.01) and CD8+ IFN-c+ T cells (2.660.1%;
p,0.01) compared to controls after 3 weeks post-vaccination.
Interestingly, highest expression of IFN-c producing CD4+
(6.960.1%) and CD8+ T cells (4.160.7%) was observed in mice
boosted with MPL-TDM in combination with liposomal rGP63,
which was comparable with mice boosted with liposomal rGP63
(CD4+ IFN-c+ T cells 5.761%; CD8+ IFN-c+ T cells 3.960.4%).
Taken together, these results indicated that liposomal rGP63
either alone or in combination with MPL-TDM during boost
seemed to modulate the immune system more efficiently than mice
receiving rGP63 plus MPL-TDM during boost. Since boosting
with liposomal Ag or liposomal Ag with MPL-TDM showed
almost comparable post vaccination immune responses, the
question we asked that whether MPL-TDM is required in
boosting or not.
Because we observed that boosting with liposomal rGP63 either
alone or in combination with MPL-TDM have accounted for
comparable vaccine efficacy before L. donovani infection, we
investigated whether this effect was also extended to experimental
systems involving challenge infection with virulent L. donovani, an
etiological agent of VL.
Role of macrophages in antileishmanial activity
It is well established that activated macrophages from
vaccinated mice inhibit Leishmania multiplication and arrest the
parasite growth efficiently [26]. To assess the activation of
antimicrobial responses elicited by macrophages to limit parasite
multiplication, murine peritoneal macrophages were isolated from
different prime-boost regimens and incubated with L. donovani
promastigotes for 4 h. We observed that the numbers of infected
macrophages from mice boosted with either rGP63 alone,
entrapped within liposomes, in association with MPL-TDM or
adjuvanted with both were significantly lower than the controls
after 72 h infection (Figure 5A). Mean number of amastigotes per
macrophage was significantly controlled in groups of mice boosted
with liposomal rGP63 with MPL-TDM than mice receiving
liposomal rGP63 alone. Thus, highest anti leishmanial activities
were observed in mice receiving liposomal rGP63 and MPL-TDM
during both prime and boost. Since stimulated macrophages
produce IL-12 (p40) in response to intracellular pathogens, we
investigated the production of this cytokine in supernatants of
macrophages infected with parasite in vitro. Although detectable
IL-12 (p40) was released from all the vaccinated mice, highest
release of IL-12 was observed in mice receiving liposomal rGP63
in association with MPL-TDM (Figure 5B). The production of IL-
12 (p40) in these macrophages correlated with the production of
NO (Figure 5C). Collectively, these results indicated that boosting
with liposomal rGP63 in presence of MPL-TDM showed highest
action toward parasite elimination in L. donovani infected
macrophages compared to mice boosted with liposomal rGP63
only.
Evaluation of parasite burden
We next analyzed the hepatic and splenic parasite load in all the
different vaccine regimens at 3 months post challenge measured by
limiting dilution. The results showed that mice boosted with
rGP63 adjuvanted with both cationic DSPC liposomes and MPL-
TDM had ,2 and ,1.5-log-fold reduced parasite burden in liver
and spleen respectively compared to mice boosted with liposomal
rGP63 only (Figure 6). Furthermore, the data shown in Figure 6
indicated that both the formulations reduced parasite burden ,5–
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7-log-fold in liver, and ,7–9.5-log-fold in spleen, compared to
unvaccinated mice. This extent of protection obtained so far has
not been achieved in subunit protein based vaccination through
s.c. route in susceptible BALB/c mice against VL.
Assessing immune correlates of protective efficacy
To understand the mechanism underlying substantial and
significant protection showed by the groups of mice receiving
MPL-TDM in combination with liposomal rGP63 during prime-
boost, we investigated the cellular and humoral responses after
challenge infection with L. donovani, identifying cell types that can
produce IFN-c and cells responsible for sustained protection.
Since previous reports described that T cell proliferation is
impaired during active VL [27], we explored Ag-induced T cell
proliferation after infection (Figure S3). Although comparable
levels of DTH and IgG isotype responses were observed in groups
of mice boosted either with liposomal rGP63 alone or in
association with MPL-TDM (data not shown), the proliferative
responses were significantly higher in mice boosted with rGP63
and MPL-TDM compared to mice boosted with liposomal rGP63
(Figure S3). Strategies that favour Th1 response during infection
have been shown to reduce Leishmania infection [28]. Moreover,
induction of IFN-c has been found to be involved in resistance to
Leishmania infection in murine model [29], and is an essential
Figure 3. Cytokine and NO production in splenocytes frommice vaccinated with different prime/boost regimens. BALB/c mice primed
with liposomal rGP63 plus MPL-TDM, followed by boosted with either rGP63 alone, in association with MPL-TDM, entrapped within liposomes, or
both before L. donovani infection. rGP63-specific (A) IFN-c, (B) IL-12 (p40), (C) NO, (D) IL-4, and (E) IL-10 were measured from cultured supernatants of
splenocytes from vaccinated mice. The results are mean6 S.E. of five individual mice per group, representative of two independent experiments with
similar results. *p,0.05, ***p,0.001 assessed by one-way ANOVA and Tukey’s multiple comparison tests, compared to PBS, unless stated.
doi:10.1371/journal.pntd.0001429.g003
MPL-TDM with Liposomal Antigen Elicits Immunity
www.plosntds.org 7 December 2011 | Volume 5 | Issue 12 | e1429
upregulator of NO production by the macrophages. In contrast,
IL-10 correlates with disease susceptibility [30]. Based on the
important roles contributed to these cytokines, we investigated the
levels of IFN-c, IL-12 (p40), (Th1 cytokines) and IL-4, IL-10 (Th2
cytokines) after 3 months of infection. Our data suggested that
boosting comprising combined adjuvants showed significantly
higher IFN-c responses (583.6616.6 pg/ml) compared to boosting
with liposomal rGP63 (531611 pg/ml) alone after 3 months post
infection (p,0.05) (Figure 7A). Since IL-12 is a potent inducer of
Th1 cells and the control of Leishmania infection requires
generation of strong Th1 response [31], we analyzed the IL-12
response in splenocytes of immunized mice after L. donovani
infection. Figure 7B showed that mice boosted with liposomal
rGP63 along with MPL-TDM exhibited significantly (p,0.05)
Figure 4. Flow cytometric analysis of rGP63-specific IFN-c producing CD4+ and CD8+ T cells. BALB/c mice were primed with liposomal
rGP63 plus MPL-TDM, followed by boosting with either rGP63 alone, in association with MPL-TDM, or liposomes, or both before challenge infection.
Splenocytes were isolated from vaccinated mice and the expression of IFN-c producing CD4+ (A) and CD8+ T (B) was studied in the presence of rGP63
(5 mg/ml). Data represent the mean of triplicate wells 6 SE of three individual mice per group. **p,0.01, ***p,0.001 assessed by two-tail t test.
doi:10.1371/journal.pntd.0001429.g004
Figure 5. Determination of macrophage activation to suppress L. donovani infection. Peritoneal macrophages were isolated from different
groups of vaccinated mice followed by in vitro infection with virulent L. donovani. The cells were stained with Giemsa for determination of
intracellular parasite numbers (A). Culture supernatants were removed at 72 h and IL-12 (p40) (B), and the NO (C) production in the medium were
estimated. Data represent mean 6 SE of three individual mice per group. *p,0.05, ***p,0.001 assessed by Student’s two-tail t test.
doi:10.1371/journal.pntd.0001429.g005
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highest IL-12p40 (214.667.7 pg/ml) compared to mice receiving
liposomal rGP63 during boost (185.466.5 pg/ml). This response
was also reflected in the generation of NO. There are significant
differences in NO production between the groups of mice
receiving either liposomal rGP63 alone or in combination with
MPL-TDM at 3 months post-infection (Figure 7C). Moreover,
combined adjuvant administration with rGP63 or mice boosted
with liposomal delivery and Ag showed comparable levels of IL-4
production. These responses were significantly lower in compar-
ison to unvaccinated mice (p,0.001) (Figure 7D). In contrast, the
Th1 suppressive cytokine, IL-10, in the mice boosted with
combined adjuvant formulations was significantly down-regulated
than mice boosted with MPL-TDM plus rGP63 (p,0.01)
(Figure 7E). Moreover, flow cytometric analysis showed
7.960.3% and 4.960.8% IFN-c producing CD4+ and CD8+,
respectively, in the L. donovani challenged liposomal rGP63 and
MPL-TDM immunized mice during prime-boost, compared with
560.9% and 3.360.4% of IFN-c producing CD4+ and CD8+,
respectively, in the liposomal rGP63 boosted L. donovani challenged
BALB/c mice (Figure 8). Therefore, mice boosted with liposomal
rGP63 in association with MPL-TDM showed significantly higher
IFN-c producing CD4+ T cells compared to mice boosted with
liposomal rGP63 (p,0.05) after 3 months L. donovani infection.
Collectively, these results suggest that combined administration of
cationic DSPC liposomes and MPL-TDM with rGP63 in a prime-
boost regimen resulted in a significantly sustained Th1 biased
immune response, which is extremely effective against L. donovani
multiplication in susceptible BALB/c mice.
Discussion
Despite the fact that the safety of protein-based subunit
vaccination makes them highly attractive for human administra-
tion, a major limitation in the development of such vaccine
remains the poor immunogenicity when used alone [32]. We
believe that the development of protein-based vaccination could
be greatly influenced by using suitable and effective adjuvant
systems that de facto promote the slow release of Ag at the site of
immunization with their ability to trigger the immune system.
With the wide assortment of vaccine strategies that are
immunologically effective, several studies have demonstrated that
combining immunomodulators with controlled-release technolo-
gies led to potent and impressive immune responses [12,33–36].
Toward this goal, our study shed new light on the approaches by
using TLR4 agonist with liposomal delivery system, through s.c.
route, in the susceptible BALB/c mouse model for translation of
experimental results into humans. In the present study, we
investigated the potentiating effects of MPL-TDM on cationic
liposomal formulation against experimental VL.
In choosing effective immunomodulators, MPL is of interest
based on its protective efficacy in experimental models of
leishmaniasis [16,37,38], and safety and immunogenicity in
humans [28]. MPL can activate the APCs through maturation
of co-stimulatory molecules, and to secrete cytokines such as IL-6,
IFN-c, IL-12 which are crucial for activation and maturation of T
and B cells [39–41]. Moreover, MPL-TDM was found to induce
Th1 biased responses [42–44]. In our recent study, we
demonstrated that vaccination with leishmanial Ag in combination
with MPL-TDM elicited protective immune response against L.
donovani challenge infection in BALB/c mice [45]. Therefore it is
speculated that the effect of MPL-TDM might be enhanced in the
presence of vaccine delivery system, such as liposomes, typically
for the protein-based vaccination. Although immunogenicity of
purified Ag is enhanced by cationic liposomal delivery [8,9,17],
several studies showed that combination of a delivery vehicle and a
Th1 inducing immunomodulator are prerequisite against Leish-
mania and tuberculosis [46–48]. Therefore, new generation
vaccines are likely to be comprised of recombinant Ags used in
conjunction with immunomodulators and delivery systems [49].
Developing effective vaccines against leishmaniasis is found to
be difficult due to lack of appropriate vaccine adjuvants. Many
attempts have been made to overcome this problem. Our earlier
reports with leishmanial antigen (LAg) entrapped within DSPC
liposomes showed protective efficacy against VL in BALB/c mice
[21]. Moreover, cationic liposomes are commonly combined with
immunomodulators to enhance the desired immune response
towards Th1. Interestingly, soluble leishmanial antigen (SLA) in
association with cationic liposomes and noncoding pDNA bearing
immunostimulatory sequences elicited impressive protective re-
sponses against VL [36]. However, in all these studies, animals
were immunized through i.p. route. In addition, recent studies
have shown that s.c. vaccination with liposomal rGP63 partially
protected susceptible BALB/c mice when challenged with L. major
promastigotes [50]. Therefore, the immune response elicited by
Figure 6. Evaluation of protection against L. donovani challenge in mice vaccinated with different vaccine regimens. Quantification of
single viable cell was determined by limiting dilution assay performed 3 months after infection on the cells isolated from liver (A) and spleen (B).
Results were expressed as log of total organ parasite burden. Data represent the mean 6 S.E of five individual mice per group, representative of two
independent experiments with similar results. *p,0.05, ** p,0.01 as assessed by one-way ANOVA and Tukey’s multiple comparison test.
doi:10.1371/journal.pntd.0001429.g006
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liposomal formulation could be modified by using MPL, a potent
immunostimulator [51]. MPL signals via TLR4, which in turn
activates the NF-kB and subsequent expression of pro-inflamma-
tory cytokines. Since s.c. administration of MPL has been found to
be successful against leishmaniasis [38], we used MPL as a
potentiator of liposomal rGP63. Here, in this study, we evaluate
the adjuvant role of MPL-TDM in liposomal rGP63 vaccine and
compared the usefulness of these adjuvants in different prime
boost regimens for the first time against VL.
Although strong adjuvanticity is prerequisite during priming,
the impact of boosting is essential to study [52]. However, the use
of heterologous prime-boost strategy in which immune response is
primed with DNA followed by boosting with recombinant protein
Ag has been successfully used in various diseases [53]. Since the
prime-boost approach can improve the effectiveness of existing
vaccines and quality of immune responses, several leishmanial Ags
have been examined against experimental VL [54]. However,
optimization of immune response of a vaccine can also be tested
by the use of different adjuvants during prime/boost with same
Ag. Interestingly, optimizing immune response by modulating
vaccine components during boost is an essential approach to
design effective vaccines [55]. In this study, we extended these
Figure 7. Cytokine and NO production in mice vaccinated with different prime/boost regimens 3 months post-infection with L.
donovani. BALB/c mice were primed with liposomal rGP63 plus MPL-TDM, followed by boosted with either rGP63 alone, in association with MPL-
TDM, entrapped within liposomes, or both after challenge with L. donovani. The cultured supernatants of splenocytes were collected, and assayed for
(A) IFN-c, (B) IL-12 (p40), (C) NO, (D) IL-4, and (E) IL-10. The results are shown as the mean absorbance values 6 S.E of five individual animals per
group, representative of two independent experiments with similar results. *p,0.05, **p,0.01, ***p,0.001 assessed by one-way ANOVA and Tukey’s
multiple comparison tests, compared to PBS, unless stated.
doi:10.1371/journal.pntd.0001429.g007
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findings by designing several vaccine formulations particularly
during boost. Following priming with liposomal rGP63 in
association with MPL-TDM, a strong immune response was
observed. Although the adjuvant effect of MPL-TDM during
boost was less than the cationic liposomes, the response was
stimulated in combination with liposomal Ag delivery. While both
the prime and boost influenced the immune response after
immunization comparably, the ultimate difference was observed
after challenge infection. Therefore, combination of delivery
systems along with MPL is a novel approach for designing
effective vaccines [51]. This adjuvant combination efficiently
inhibited L. donovani multiplication in macrophages in vitro when
administered during both prime and boost. Resistance to
leishmaniasis is associated with a predominant IFN-c and IL-12
production from the Ag-specific T cells [56,57]. The results of the
current study showed significantly higher levels of IFN-c, and IL-
12 (p40) in groups of mice receiving rGP63 in presence of
liposomes and MPL-TDM during prime and boost than mice
receiving liposomal rGP63 during boost, after L. donovani challenge
infection. While MPL is reported to promote IFN- c production
by Ag-specific CD4+ T cells and skewing the immune response
towards Th1 type [40], liposomal Ag showed protective response
against leishmaniasis [21]. Because, NO is generated after
macrophage activation by IFN-c and plays an important role in
controlling leishmaniasis [58], we measured the NO content in
splenocytes of all vaccinated mice after L. donovani infection.
Significantly higher NO was obtained in mice receiving combined
adjuvant formulations than mice boosted with liposomal rGP63.
To this end, the protective response showed that vaccination with
liposomal rGP63 along with MPL-TDM showed almost 2-log-
fold, and 7–10-log-fold reduction in parasite burden compared to
mice boosted with liposomal rGP63 and unvaccinated mice,
respectively. The ultimate impact of boosting was seen after
challenge infection might be due to high Th1-biased response.
Therefore, a clear requirement of all the vaccine components
(rGP63, MPL-TDM, and liposomes) was evident for both priming
and boosting. Until now, this extent of protection achieved using
recombinant protein-based subunit vaccination formulated with
MPL-TDM and a delivery system has not been achieved with any
other subunit protein-based vaccination against experimental VL.
In conclusion, the advantage of simultaneous administration of
liposomal Ag and TLR ligand through s.c. route is efficacious
against experimental VL. This is the first report of using different
prime/boost approach with TLR4 ligand along with liposomal
delivery of subunit vaccination against experimental VL in
susceptible BALB/c mice. This formulation resulted in activation
of DCs, increased T cell response, higher IgG2a/IgG1 ratio
resulting in superior protection against L. donovani infection.
Supporting Information
Figure S1 Liposomal rGP63 plus MPL-TDM induced
antibody response. rGP63-specific IgG isotype responses in
mice immunized with either rGP63 alone, or in association with
MPL-TDM, or DSPC-cationic liposomes, or both after immuni-
zation. 3 wks after last immunization, serum samples were
collected and assayed for rGP63-specific (A) IgG2a and (B) IgG1
and (C) ratio of IgG2a/IgG1. The results are shown as the mean
absorbance values 6 S.E of five individual animals per group,
representative of two independent experiments with similar results.
**p,0.01, ***p,0.001 assessed by one-way ANOVA and Tukey’s
multiple comparison tests, compared to PBS, unless stated.
(TIF)
Figure S2 Antibody response in different prime/boost
regimens before challenge infection. rGP63-specific IgG
isotype responses in BALB/c mice primed with liposomal rGP63
plus MPL-TDM, followed by boosted with either rGP63 alone, in
association with MPL-TDM, entrapped within liposomes, or both
before challenge infection. 3 wks after last immunization, serum
samples were collected and assayed for rGP63-specific (A) IgG2a
and (B) IgG1 and (C) ratio of IgG2a/IgG1. The results are shown
as the mean absorbance values 6 S.E of five individual animals
per group, representative of two independent experiments with
similar results. *p,0.05, ***p,0.001 assessed by one-way
ANOVA and Tukey’s multiple comparison tests, compared to
PBS, unless stated.
(TIF)
Figure S3 rGP63-specific splenocyte proliferation after
L. donovani infection. Spleens were collected from vaccinated
mice following 3 months post-infection, restimulated in vitro for
72 h with rGP63 (2.5 mg/ml). rGP63-specific splenocyte prolifer-
ation was determined by thymidine incorporation and expressed
as counts per minute. The results are the mean values 6 S.E of
five individual animals per group, representative of two indepen-
Figure 8. Flow cytometric analysis of rGP63-specific IFN-c producing CD4+ CD8+ T cells after challenge infection. Mice were primed
with liposomal rGP63 plus MPL-TDM, followed by boosting with either rGP63 alone, in association with MPL-TDM, entrapped within liposomes, or
both after challenge with L. donovani. Splenocytes were isolated from vaccinated mice at 3 months after challenge infection and the expression of
IFN-c producing CD4+ (A) and CD8+ (B) T was studied in the presence of rGP63 (5 mg/ml). Data represent the mean of triplicate wells 6 SE of three
individual mice per group. *p,0.05, **p,0.01, ***p,0.001 assessed by Student’s two-tail t test.
doi:10.1371/journal.pntd.0001429.g008
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dent experiments with similar results. *p,0.05, ***p,0.001
assessed by one-way ANOVA and Tukey’s multiple comparison
tests.
(TIF)
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